Actinogen (ASX:ACW) has reported success in using its novel antidepressant Xanamem to mitigate the symptoms of major depression based on a daily 10mg dose. Shares in the microcap stock soared 30% to 3.1cps on a volume of 15M+ shares in the first half hour of trade, according to The Market Online data. Xanamem, unlike other mainstream antidepressants which seek to alter serotonin and dopamine, has a novel way of operating – it simply blocks cortisol. Cortisol is well known as ‘the stress hormone,’ given it peaks in blood when patients are undergoing stress. The hormones have also been found, in…
